Abstract
Patients with one or more low-grade bladder tumors of the urinary bladder will often develop a subsequent tumor but these so called “recurrences” are almost always of similar grade and rarely invade beyond the basement membrane. Therefore, the clinician should try to minimize the morbidity associated with treating these new tumors. Since many of these patients are elderly or have comorbidities, active surveillance is a very reasonable initial approach if these tumors are very small and appear low-grade. Another alternative is fulguration in the outpatient setting using a flexible cystoscope and electrode. The goal is to try to avoid the hospital and performing a formal transurethral resection. This adds potential morbidity, inconvenience, and cost.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29.
Rübben H, Lutzeyer W, Fischer N, Deutz F, Lagrange W, Giani G. Natural history and treatment of low and high risk superficial bladder tumors. J Urol. 1988;139:283–5.
Prout GR, Barton BA, Griffin PP, Friedell GH. Treated history of noninvasive grade 1 transitional cell carcinoma. The National Bladder Cancer Group. J UroL. 1992;148:1413–9.
Sylvester RJ, van der Meijden APM, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49:466–5. discussion 475–7.
van Rhijn BWG, Burger M, Lotan Y, Solsona E, Stief CG, Sylvester RJ, et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol. 2009;56:430–42.
Burger M, Catto JWF, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013;63:234–41.
Nielsen ME, Smith AB, Meyer A-M, Kuo T-M, Tyree S, Kim WY, et al. Trends in stage-specific incidence rates for urothelial carcinoma of the bladder in the United States: 1988 to 2006. Cancer. 2014;120:86–95.
Holmäng S, Andius P, Hedelin H, Wester K, Busch C, Johansson SL. Stage progression in Ta papillary urothelial tumors: relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy. J Urol. 2001;165:1124–8. discussion 1128–30.
Lapham RL, Ro JY, Staerkel GA, Ayala AG. Pathology of transitional cell carcinoma of the bladder and its clinical implications. Semin Surg Oncol. 1997;13:307–18.
Soloway MS, Bruck DS, Kim SS. Expectant management of small, recurrent, noninvasive papillary bladder tumors. J Urol. 2003;170:438–41.
Gofrit ON, Pode D, Lazar A, Katz R, Shapiro A. Watchful waiting policy in recurrent Ta G1 bladder tumors. Eur Urol. 2006;49:303–6. discussion 306–7.
Pruthi RS, Baldwin N, Bhalani V, Wallen EM. Conservative management of low risk superficial bladder tumors. J Urol. 2008;179:87–90. discussion 90.
Gofrit ON, Shapiro A. Active surveillance of low grade bladder tumors. Arch Ital Urol Androl. 2008;80:132–5.
Hernández V, Alvarez M, la Peña de E, Amaruch N, Martín MD, La Morena de JM, et al. Safety of active surveillance program for recurrent nonmuscle-invasive bladder carcinoma. Urology. 2009;73:1306–10.
Jordan AM, Weingarten J, Murphy WM. Transitional cell neoplasms of the urinary bladder. Can biologic potential be predicted from histologic grading? Cancer. 1987;60:2766–74.
Herr HW. Does cystoscopy correlate with the histology of recurrent papillary tumours of the bladder? BJU Int. 2001;88:683–5.
Hall MC, Chang SS, Dalbagni G, Pruthi RS, Seigne JD, Skinner EC, et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol. 2007;178:2314–30.
Manikandan R, Lynch N, Grills RJ. Percutaneous peritoneal drainage for intraperitoneal bladder perforations during transurethral resection of bladder tumors. J Endourol. 2003;17:945–7.
Collado A, Chéchile GE, Salvador J, Vicente J. Early complications of endoscopic treatment for superficial bladder tumors. J Urol. 2000;164:1529–32.
Balbay MD, Cimentepe E, Unsal A, Bayrak O, Koç A, Akbulut Z. The actual incidence of bladder perforation following transurethral bladder surgery. J Urol. 2005;174:2260–2. discussion 2262–3.
Weldon TE, Soloway MS, Persky L. Urothelial susceptibility to neoplastic cellular implantation. Surg Forum. 1974;25:547–9.
Weldon TE, Soloway MS. Susceptibility of urothelium to neoplastic cellular implantation. Urology. 1975;5:824–7.
Soloway MS, Masters S. Urothelial susceptibility to tumor cell implantation: influence of cauterization. Cancer. 1980;46:1158–63.
Soloway MS, Nissenkorn I, McCallum L. Urothelial susceptibility to tumor cell implantation: comparison of cauterization with N-methyl-N-nitrosourea. Urology. 1983;21:159–61.
Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics. 2003;21:1315–30.
Svatek RS, Hollenbeck BK, Holmäng S, Lee R, Kim SP, Stenzl A, et al. The economics of bladder cancer: costs and considerations of caring for this disease. Eur Urol. 2014;66:253–62.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
Zachary L. Smith declares no potential conflicts of interest.
Mark S. Soloway is the Editor-in-Chief of Current Urology Reports.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Rights and permissions
About this article
Cite this article
Smith, Z.L., Soloway, M.S. Expectant Management of Low-Risk Bladder Cancer. Curr Urol Rep 16, 82 (2015). https://doi.org/10.1007/s11934-015-0555-1
Published:
DOI: https://doi.org/10.1007/s11934-015-0555-1